BIO
Bio-Rad Laboratories, Inc.
NYSE · Healthcare · Medical - Devices · US
$386.11
−0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.6B | 2.6B | 2.6B | 2.7B | 2.8B |
| Cost of Revenue | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Gross Profit | 1.3B | 1.3B | 1.4B | 1.4B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 261.1M | 256.9M | 295.9M | 247.4M | 256.9M |
| SG&A Expense | 847.8M | 819.9M | 814.0M | 841.7M | 827.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Cost and Expenses | 2.4B | 2.3B | 2.3B | 2.3B | 2.3B |
| Operating Income (EBIT) | 235.0M | 270.5M | 269.0M | 337.8M | 482.6M |
| Non-Operating | |||||
| Interest Income | 88.0M | 95.5M | 82.0M | 100.9M | 58.0M |
| Interest Expense | 36.7M | 49.0M | 48.9M | 49.4M | 38.1M |
| Net Interest Income | 51.3M | 46.5M | 33.1M | 51.5M | 19.9M |
| Other Non-Op Income/Expense | 115.4M | 725.0M | (2.6B) | (1.2B) | (5.2B) |
| Non-Operating Income (excl Interest) | (152.1M) | (774.0M) | 2.6B | 1.1B | 5.1B |
| EBT (Pre-Tax Income) | 350.4M | 995.5M | (2.3B) | (850.1M) | (4.7B) |
| Income Tax Expense | 128.0M | 235.6M | (498.3M) | (212.8M) | (1.1B) |
| Bottom Line | |||||
| Net Income | 222.4M | 759.9M | (1.8B) | (637.3M) | (3.6B) |
| Earnings from Cont. Ops | 222.4M | 759.9M | (1.8B) | (637.3M) | (3.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 222.4M | 759.9M | (1.8B) | (637.3M) | (3.6B) |
| Per Share | |||||
| Basic EPS | $8.33 | $27.87 | ($65.36) | ($21.82) | ($121.79) |
| Diluted EPS | $8.25 | $27.87 | ($65.36) | ($21.82) | ($121.79) |
| Revenue Per Share | $96.81 | $94.75 | $90.97 | $91.45 | $94.08 |
| Shares | |||||
| Basic Shares Outstanding | 26.7M | 27.3M | 28.2M | 29.2M | 29.8M |
| Diluted Shares Outstanding | 26.8M | 27.3M | 28.2M | 29.2M | 29.8M |
| Profitability Metrics | |||||
| EBITDA | 534.6M | 1.2B | (2.1B) | (654.8M) | (4.5B) |
| D&A | 147.5M | 205.4M | 151.6M | 145.9M | 177.2M |
| EBIT | 387.1M | 1.0B | (2.3B) | (800.7M) | (4.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026